Bacteria: Gram-positive

Group A Streptococcus

Streptococcus pyogenes

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A beta-hemolytic Gram-positive coccus in chains.

Infections

Pharyngitis, impetigo, cellulitis, necrotizing fasciitis, scarlet fever, toxic shock syndrome; rheumatic fever and glomerulonephritis afterwards.

Signs and symptoms

Sore throat with fever and tender neck nodes; spreading red skin infection; pain out of proportion to appearance in necrotizing infection.

Antibiotic and antimicrobial resistance

Universally susceptible to penicillin; macrolide and clindamycin resistance occur (erm).

Treatment considerations

Penicillin or amoxicillin; cephalexin for skin infection; clindamycin is added in severe invasive infection.

Infection control and public health

Invasive group A Streptococcus is reportable; clusters in facilities need investigation.

Chains of Streptococcus pyogenes cocci, stained
Streptococcus pyogenes (group A) chains, Pappenheim stain, 900×. CDC; public domain. Image source
Gram-positive cocci in pairs and chains, schematic
Gram-positive cocci in pairs and chains. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Group A streptococcal disease.
  2. IDSA. Streptococcal Pharyngitis guideline.
  3. IDSA. Skin and Soft Tissue Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.